Literature DB >> 20375875

Impact of HIV infection, highly active antiretroviral therapy, and hepatitis C coinfection on serum interleukin-27.

Christina Guzzo1, Wilma M Hopman, Nor Fazila Che Mat, Wendy Wobeser, Katrina Gee.   

Abstract

A newly described cytokine, interleukin-27 (IL-27), that activates naive CD4 T cells, has recently been shown to be an anti-HIV cytokine. However, the effect of HIV infection on IL-27 expression has not been characterized. We found that clinical characteristics, including HIV viral load, hepatitis C virus coinfection, and CD4 T cell counts, were associated with changes in serum IL-27. Overall, our results suggest circulating HIV may suppress IL-27, a critical concept in treatment development with this cytokine.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20375875     DOI: 10.1097/QAD.0b013e3283391d2b

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  15 in total

1.  IL-27 and IL-21 are associated with T cell IL-10 responses in human visceral leishmaniasis.

Authors:  Nasim Akhtar Ansari; Rajiv Kumar; Shalini Gautam; Susanne Nylén; Om Prakash Singh; Shyam Sundar; David Sacks
Journal:  J Immunol       Date:  2011-02-28       Impact factor: 5.422

2.  Influenza A virus induces interleukin-27 through cyclooxygenase-2 and protein kinase A signaling.

Authors:  Li Liu; Zhongying Cao; Jing Chen; Rui Li; Yanhua Cao; Chengliang Zhu; Kailang Wu; Jianguo Wu; Fang Liu; Ying Zhu
Journal:  J Biol Chem       Date:  2012-02-16       Impact factor: 5.157

Review 3.  Modulation of inflammation by interleukin-27.

Authors:  Markus Bosmann; Peter A Ward
Journal:  J Leukoc Biol       Date:  2013-07-31       Impact factor: 4.962

4.  Complement activation product C5a is a selective suppressor of TLR4-induced, but not TLR3-induced, production of IL-27(p28) from macrophages.

Authors:  Markus Bosmann; Mikel D Haggadone; Mark R Hemmila; Firas S Zetoune; J Vidya Sarma; Peter A Ward
Journal:  J Immunol       Date:  2012-04-09       Impact factor: 5.422

Review 5.  Evaluating the potential of IL-27 as a novel therapeutic agent in HIV-1 infection.

Authors:  Sanjay Swaminathan; Lue Dai; H Clifford Lane; Tomozumi Imamichi
Journal:  Cytokine Growth Factor Rev       Date:  2013-08-17       Impact factor: 7.638

6.  IL-27-induced gene expression is downregulated in HIV-infected subjects.

Authors:  Christina Guzzo; Wilma M Hopman; Nor Fazila Che Mat; Wendy Wobeser; Katrina Gee
Journal:  PLoS One       Date:  2012-09-25       Impact factor: 3.240

7.  IL-27 inhibits HIV-1 infection in human macrophages by down-regulating host factor SPTBN1 during monocyte to macrophage differentiation.

Authors:  Lue Dai; Kristy B Lidie; Qian Chen; Joseph W Adelsberger; Xin Zheng; DaWei Huang; Jun Yang; Richard A Lempicki; Tauseef Rehman; Robin L Dewar; Yanmei Wang; Ronald L Hornung; Kelsey A Canizales; Stephen J Lockett; H Clifford Lane; Tomozumi Imamichi
Journal:  J Exp Med       Date:  2013-03-04       Impact factor: 14.307

8.  IL-27 increases BST-2 expression in human monocytes and T cells independently of type I IFN.

Authors:  Christina Guzzo; Masany Jung; Ashley Graveline; Bruce W Banfield; Katrina Gee
Journal:  Sci Rep       Date:  2012-12-13       Impact factor: 4.379

9.  Interleukin-27 is a potent inhibitor of cis HIV-1 replication in monocyte-derived dendritic cells via a type I interferon-independent pathway.

Authors:  Qian Chen; Sanjay Swaminathan; De Yang; Lue Dai; Hongyan Sui; Jun Yang; Ronald L Hornung; Yanmei Wang; Da Wei Huang; Xiaojun Hu; Richard A Lempicki; Tomozumi Imamichi
Journal:  PLoS One       Date:  2013-03-20       Impact factor: 3.240

10.  Plasma interleukin-27 (IL-27) levels are not modulated in patients with chronic HIV-1 infection.

Authors:  Sanjay Swaminathan; Zonghui Hu; Adam W Rupert; Jeanette M Higgins; Robin L Dewar; Randy Stevens; Qian Chen; Catherine A Rehm; Julia A Metcalf; Michael W Baseler; H Clifford Lane; Tomozumi Imamichi
Journal:  PLoS One       Date:  2014-06-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.